AURORA Study: Preventing Further Lung Damage in IPF

Trial Objectives

Idiopathic pulmonary fibrosis, or IPF, causes scarring in the lungs, making it more difficult to breathe. The cause of IPF is currently unknown, but it is believed to be related to a continuous injury response in the lungs that does not switch off. The study medication, known as CAL101, targets a protein called S100A4 that is wrongly activated in IPF and contributes to scar tissue buildup. Researchers want to know if this treatment can help reduce scar tissue production and prevent further damage to the lungs.

In this study, volunteers will be randomly assigned to receive IV infusions of either the study medicine or a placebo (a medication containing no active ingredients). Infusions will occur at clinic appointments, taking about an hour. Participants will be monitored for an hour after treatment. They also will receive physical exams to monitor symptoms and report on any adverse events they experience.